A liquid chromatography-tandem mass spectrometry method for the quantification of PAC-1 in rat plasma

Journal of Pharmaceutical and Biomedical Analysis

Volumn 54, Issue 1, 2011, Pages 225-229

  Fang, Li Na ^a   Chen, Xiao Hui ^a   Wang, Qiu Di ^a   Zhang, Di ^a   Zhao, Juan Juan ^a   Long, Zhi Min ^a   Gong, Ping ^a   Bi, Kai Shun ^a  

^a SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Anticancer agent; LC MS MS; PAC 1; Pharmacokinetics; Plasma

Indexed keywords

1 PIPERAZINEACETIC ACID 4 (PHENYLMETHYL) 2 [[2 HYDROXY 3 (2 PROPEN 1 YL)PHENYL]METHYLENE]HYDRAZIDE; ACETONITRILE; ANTINEOPLASTIC AGENT; METHANOL; PROCASPASE ACTIVATING COMPOUND 1; UNCLASSIFIED DRUG; WATER;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG STABILITY; ELECTROSPRAY MASS SPECTROMETRY; FEMALE; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETER; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; PROCESS OPTIMIZATION; QUADRUPOLE MASS SPECTROMETRY; RAT; SENSITIVITY AND SPECIFICITY; SEX DIFFERENCE; TANDEM MASS SPECTROMETRY; THERMOSTABILITY; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADMINISTRATION, ORAL; ANIMALS; CALIBRATION; CASPASES; CHEMISTRY TECHNIQUES, ANALYTICAL; CHEMISTRY, PHARMACEUTICAL; CHROMATOGRAPHY, LIQUID; FEMALE; HYDRAZONES; KINETICS; MALE; MODELS, CHEMICAL; PIPERAZINES; RATS; RATS, WISTAR; REPRODUCIBILITY OF RESULTS; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; TANDEM MASS SPECTROMETRY;

EID: 77957021257     PISSN: 07317085     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpba.2010.07.042     Document Type: Article

References (19)

1. Putt K.S., Chen G.W., Pearson J.M., Sandhorst J.S., Hoagland M.S., Kwon J.T., Hwang S.K., Jin H., Churchwell M.I., Cho M.H., Doerge D.R., Helferich W.G., Hergenrother P.J. Small-molecule activation of procaspase-3 to caspase-3 as a personalized anticancer strategy. Nat. Chem. Boil. 2006, 2:543-550.
2. P.J. Hergenrother, K.S. Put, G.W. Chen, WO 2006/128173 A2.
3. Peterson Q.P., Goode D.R., West D.C., Ramsey A.N., Lee J.Y., Hergenrother P.J. PAC-1 activates procaspase-3 in vitro through relief of zinc-mediated inhibition. J. Mol. Biol. 2009, 388:144-158.
4. Peterson Q.P., Hsu D.C., Goode D.R., Novotny C.J., Totten R.K., Hergenrother P.J. Procaspase-3 activation as an anti-cancer strategy: structure-activity relationship of procaspase-activating compound 1 (PAC-1) and its cellular co-location with caspase-3. J. Med. Chem. 2009, 52:5721-5731.
5. Roy S., Bayly C.I., Gareau Y., Houtzager V.M., Kargman S., Keen S.L., Rowland K., Seiden I.M., Thornberry N.A., Nicholson D.W. Maintenance of caspase-3 proenzyme dormancy by an intrinsic " safety catch" regulatory tripeptide. Proc. Natl. Acad. Sci. U.S.A. 2001, 98:6132-6137.
6. Nakagawara A., Nakamura Y., Ikeda H., Hiwasa T., Kuida K., Su M.S., Zhao H., Cnaan A., Sakiyama S. High levels of expression and nuclear localization of interleukin-1 beta converting enzyme (ICE) and CPP32 in favorable human neuroblastomas. Cancer Res. 1997, 57:4578-4584.
7. Izban K.F., Wrone-Smith T., Hsi E.D., Schnitzer B., Quevedo M.E., Alkan S. Characterization of the interleukin-1 beta-converting enzyme/Ced-3-family protease, caspase-3/CPP32, in Hodgkin's disease-lack of caspase-3 expression in modular lymphocyte predominance Hodgkin's disease. Am. J. Pathol. 1999, 154:1439-1447.
8. Persad R., Liu C., Wu T.T., Houlihan P.S., Hamilton S.R., Diehl A.M., Rashid A. Overexpression of caspase-3 in hepatocellular carcinomas. Modern Pathol. 2004, 17:861-867.
9. Svingen P.A., Loegering D., Rodriquez J., Meng X.W., Mesner P.W., Holbeck S., Monks A., Krajewski S., Scudiero D.A., Sausville E.A., Reed J.C., Lazebnik Y.A., Kaufmann S.H. Components of the cell death machine and drug sensitivity of the National Cancer Institute cell line panel. Clin. Cancer Res. 2004, 10:6807-6820.
10. Song Z., Chen X.H., Zhang D., Ren L., Fang L.N., Cheng W.M., Gong P., Bi K.S. Kinetic study of the degradation of PAC-1 and identification of a degradation product in alkaline condition. Chromatographia 2009, 70:1575-1580.
11. Song Z., Chen X.H., Zhang D., Gong P., Bi K.S. Isolation and structure elucidation of degradation products in the potential anticancer drug PAC-1. J. Pharm. Biomed. Anal. 2010, 51:965-968.
12. Ren L., Bi K.S., Gong P., Cheng W.M., Song Z., Fang L.N., Chen X.H. Characterization of the in vivo and in vitro metabolic profile of PAC-1 using liquid chromatography-mass spectrometry. J. Chromatogr. B 2008, 876:47-53.
13. Fang L.N., Chen X.H., Song Z., Wang G., Zhao X., Ren L., Gong P., Bi K.S. Development of a high performance liquid chromatography method for quantification of PAC-1 in rat plasma. J. Pharm. Biomed. Anal. 2009, 49:447-450.
14. Harris R.Z., Benet L.Z., Schwartz J.B. Gender effects in pharmacokinetics and pharmacodynamics. Drugs 1995, 50:222-239.
15. Beierle I., Meibohm B., Derendorf H. Gender differences in pharmacokinetics and pharmacodynamics. Int. J. Clin. Pharmacol. Ther. 1999, 37:529-547.
16. Vettorazzi A., Gonzalez-Penas E., Troconiz I.F., Arbillaga L., Corcuera L.A., Gil A.G., Lopez de cerain A. A different kinetic profile of ochratoxin A in mature male rats. Food Chem. Toxicol. 2009, 47:1291-1297.
17. Molpeceres J., Chacon M., Guzman M., Aberturas M.R., Berges L. Dependency of cyclosporine tissue distribution and metabolism on the age and gender of rats after a single intravenous dose. Int. J. Pharm. 2000, 197:129-141.
18. Niwa T., Kaneko H., Naritomi Y., Togawa A., Shiraga T., Iwasaki K., Tozuka Z., Hata T. Species and sex differences of testosterone and nifedipine oxidation in liver microsomes of rat, dog and monkey. Xenobiotica 1995, 25:1041-1049.
19. Guidance for Industry, Bioanalytical Method Validation (updated 2001), http://www.fda.gov/cder/guidance/index.htm.